There wasn't anything in Novo Nordisk's (NYSE:NVO) second-quarter results to get too excited about, and it appears the company will continue to face pricing pressure for its diabetes drugs from payers next year as well.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,